Europe
They will focus on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such and rheumatoid arthritis.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
On Tuesday, the White House notified Congress and the United Nations of the decision. However, the withdrawal will not be immediate.
Kiadis Pharma, based in Amsterdam, The Netherlands, licensed a previously undisclosed K-NK0004 program to Paris-based Sanofi.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its MELANI-01 trial.
As countries reopen businesses and move toward normalcy, emerging biotech companies in the U.S. and Europe have encountered a mixed bag of experiences.
ObsEva, based in Geneva, Switzerland and Boston, Massachusetts, announced topline data from the PRIMROSE 1 and 2 Phase III trials of Yselty (linzagolix) for uterine fibroids.
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
PRESS RELEASES